Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting

The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tookman, Laura, Krell, Jonathan, Nkolobe, Baleseng, Burley, Laura, McNeish, Iain A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257860/
https://www.ncbi.nlm.nih.gov/pubmed/32523631
http://dx.doi.org/10.1177/1758835920921980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257860/
https://www.ncbi.nlm.nih.gov/pubmed/32523631
http://dx.doi.org/10.1177/1758835920921980

Ejemplares similares